{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Biogen Pharmachem Industries Ltd
Biogen Pharma's Q1 FY25 Financial Report Shows Decline in Performance, Receives 'Sell' Rating
Biogen Pharma's Stock Soars with Strong Performance and Bullish Trend
Biogen Pharmachem Industries, a microcap trading company, had a strong start to the day with a 4.86% gain, outperforming the sector by 1.05%. The stock has been on a 3-day consecutive gain streak, rising 5.84%. It is also trading higher than its moving averages, indicating a bullish trend. However, MarketsMOJO has given a 'Sell' call for the stock, advising investors to do their own research before investing.
Biogen Pharmachem Industries Receives 'Sell' Rating After Bulk Deals on Stock Market
Biogen Pharmachem Industries, a microcap trading company, received a 'Sell' rating from MarketsMOJO after recent bulk deals on the stock market. Despite this, the company has been performing well, outperforming the sector by 1.05% and showing consecutive gains for the last 3 days. It has also outperformed the Sensex with a 74.70% increase in the last 1 month.
Biogen Pharma's Q3 financials show mixed results
Biogen Pharmachem Industries, a microcap trading company, reported a 75.61% growth in standalone net profit for the quarter ended September 2023. However, the operating profit showed a decline of 110.00%. The company's half-yearly profit after tax has increased, but there are concerns about its debtors turnover ratio and quarterly profit before tax. MarketsMOJO has given a 'Sell' call for the company's stock.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}